<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">16906016</PMID>
        <DateCompleted>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1744-6872</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenetics and genomics</Title>
                <ISOAbbreviation>Pharmacogenet. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>615-23</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Methotrexate (MTX) represents the antirheumatic drug mainly used in rheumatoid arthritis (RA). HLA-G antigens are inducible nonclassical major histocompatibility complex class Ib molecules important for maintaining anti-inflammatory conditions. The HLA-G gene is characterized by a deletion/insertion polymorphism of 14 bp that controls specific mRNA stability and protein levels. It has been reported that MTX therapy mediates an increase of interleukin-10-producing cells. This cytokine up-regulates HLA-G expression. For this, we tested the hypothesis of an MTX-mediated HLA-G production and the possible relationship with the HLA-G 14-bp polymorphism.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Peripheral blood mononuclear cells from healthy individuals and non-MTX-treated RA patients were activated with different MTX concentrations, and soluble HLA-G (sHLA-G) and interleukin-10 production was investigated by specific immunoenzymatic assay. HLA-G 14-bp polymorphism genotyping was performed in healthy individuals and RA patients, defined as 'responders' and 'nonresponders' to the MTX therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MTX activation induces the production of sHLA-G molecules. A significant association was observed between the highest sHLA-G1 concentrations and the -14/-14 bp genotype. The analysis of the HLA-G 14-bp polymorphism in MTX-treated RA patients has confirmed an increase of the -14/-14 bp genotype in the responder group (chi=6.12, P=0.02; chi test) (odds ratio=2.46 (95% confidence interval, 1.26-4.84) P=0.009; logistic regression model).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results propose that the MTX induces the production of the anti-inflammatory sHLA-G molecules that concur with the therapy response. Furthermore, the association between -14/-14 bp genotype and MTX clinical outcome proposes this polymorphism as a therapy marker in the early phases of the disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rizzo</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Medical Genetics, Department of Experimental and Diagnostic Medicine University of Ferrara, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubini</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Govoni</LastName>
                    <ForeName>Marcello</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Padovan</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melchiorri</LastName>
                    <ForeName>Loredana</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stignani</LastName>
                    <ForeName>Marina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carturan</LastName>
                    <ForeName>Sabrina</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferretti</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trotta</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baricordi</LastName>
                    <ForeName>Olavio R</ForeName>
                    <Initials>OR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D023362">Evaluation Studies</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacogenet Genomics</MedlineTA>
            <NlmUniqueID>101231005</NlmUniqueID>
            <ISSNLinking>1744-6872</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>130068-27-8</RegistryNumber>
                <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
                <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059951" MajorTopicYN="N">HLA-G Antigens</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007962" MajorTopicYN="N">Leukocytes</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>12</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16906016</ArticleId>
            <ArticleId IdType="doi">10.1097/01.fpc.0000230115.41828.3a</ArticleId>
            <ArticleId IdType="pii">01213011-200609000-00001</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15888487</PMID>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0964-6906</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>14</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jul</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1745-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Warfarin, a commonly prescribed anticoagulant, exhibited large inter-individual and inter-ethnic differences in the dose required for its anticoagulation effect. Asian populations, including Chinese, require a much lower maintenance dose than Caucasians, for which the mechanisms still remain unknown. We determined DNA sequence variants in CYP2C9 and VKORC1 in 16 Chinese patients having warfarin sensitivity (&lt; or = 1.5 mg/day, n = 11) or resistance (&gt; or = 6.0 mg/day, n = 5), 104 randomly selected Chinese patients receiving warfarin, 95 normal Chinese controls and 92 normal Caucasians. We identified three CYP2C9 variants, CYP2C9*3, T299A and P382L, in four warfarin-sensitive patients. A novel VKORC1 promoter polymorphism (-1639 G &gt; A) presented in the homozygous form (genotype AA) was found in all warfarin-sensitive patients. The resistant patients were either AG or GG. Among the 104 randomly selected Chinese patients receiving warfarin, AA genotype also had lower dose than the AG/GG genotype (P &lt; 0.0001). Frequencies of AA, AG and GG genotypes were comparable in Chinese patients receiving warfarin (79.7, 17.6 and 2.7%) and normal Chinese controls (82, 18 and 0%), but differed significantly from Caucasians (14, 47 and 39%) (P &lt; 0.0001). The promoter polymorphism abolished the E-box consensus sequences and dual luciferase assay revealed that VOKRC1 promoter with the G allele had a 44% increase of activity when compared with the A allele. The differences in allele frequencies of A/G allele and its levels of VKORC1 promoter activity may underscore the inter-individual differences in warfarin dosage as well as inter-ethnic differences between Chinese and Caucasians.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Hsiang-Yu</ForeName>
                    <Initials>HY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedical Sciences, academia Sinica, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jin-Jer</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>M T Michael</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wung</LastName>
                    <ForeName>Ju-Chieh</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ying-Fu</ForeName>
                    <Initials>YF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Charng</LastName>
                    <ForeName>Min-Ji</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Ming-Jen</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hung</LastName>
                    <ForeName>Chi-Ren</ForeName>
                    <Initials>CR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Chun-Yu</ForeName>
                    <Initials>CY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Chien-Hsiun</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jer-Yuarn</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yuan-Tsong</ForeName>
                    <Initials>YT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>05</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
                <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.-</RegistryNumber>
                <NameOfSubstance UI="D006899">Mixed Function Oxygenases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.-</RegistryNumber>
                <NameOfSubstance UI="C450260">CYP2C9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.-</RegistryNumber>
                <NameOfSubstance UI="D065729">Cytochrome P-450 CYP2C9</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.17.4.4</RegistryNumber>
                <NameOfSubstance UI="C578523">VKORC1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.17.4.4</RegistryNumber>
                <NameOfSubstance UI="D064417">Vitamin K Epoxide Reductases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065729" MajorTopicYN="N">Cytochrome P-450 CYP2C9</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006899" MajorTopicYN="N">Mixed Function Oxygenases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064417" MajorTopicYN="N">Vitamin K Epoxide Reductases</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15888487</ArticleId>
            <ArticleId IdType="pii">ddi180</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddi180</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28371569</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1099-0496</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric pulmonology</Title>
                <ISOAbbreviation>Pediatr. Pulmonol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pseudomonas eradication and clinical effectivness of Ivacaftor in four Hispanic patients with S549N.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E37-E39</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.23665</ELocationID>
            <Abstract>
                <AbstractText>Ivacaftor was approved for rarer class-III CFTR mutations including S549N in 2014. Since these mutations are uncommon, ongoing reports of patient experiences with Ivacaftor and these mutations are important. This case series describes the clinical effectiveness (including airway infection status, lung function, and growth) of Ivacaftor therapy in four pediatric Hispanic patients with S549N and F508del over 24 months. In these patients, Ivacaftor was highly efficacious with no further Pseudomonas-positive cultures despite prior chronic colonization in three patients as well as notable improvements in lung function and growth. The remarkable improvements in lung function and growth were similar to G551D patients with more striking changes in airway infection status. Pediatr Pulmonol 2017;52:E37-E39. © 2017 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>© 2016 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Strang</LastName>
                    <ForeName>Abigail</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pulmonology, A.I. duPont Hospital for Children, Wilmington, Delaware.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fischer</LastName>
                    <ForeName>Anthony J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Iowa Children's Hospital, Iowa City, Iowa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chidekel</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pulmonology, A.I. duPont Hospital for Children, Wilmington, Delaware.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pediatr Pulmonol</MedlineTA>
            <NlmUniqueID>8510590</NlmUniqueID>
            <ISSNLinking>1099-0496</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000627">Aminophenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C505032">CFTR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>126880-72-6</RegistryNumber>
                <NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1Y740ILL1Z</RegistryNumber>
                <NameOfSubstance UI="C545203">ivacaftor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D041923" MajorTopicYN="N">Adolescent Development</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000627" MajorTopicYN="N">Aminophenols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003550" MajorTopicYN="N">Cystic Fibrosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019005" MajorTopicYN="N">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006630" MajorTopicYN="N">Hispanic Americans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011549" MajorTopicYN="N">Pseudomonas</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011552" MajorTopicYN="N">Pseudomonas Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cystic fibrosis</Keyword>
            <Keyword MajorTopicYN="N">pharmacology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28371569</ArticleId>
            <ArticleId IdType="doi">10.1002/ppul.23665</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25209194</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-485X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>165B</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title>
                <ISOAbbreviation>Am. J. Med. Genet. B Neuropsychiatr. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness.</ArticleTitle>
            <Pagination>
                <MedlinePgn>635-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.b.32268</ELocationID>
            <Abstract>
                <AbstractText>Literature indicates key role of glutamatergic pathway genes in antipsychotic response among schizophrenia patients. However, molecular basis of their underlying role in antipsychotic response remained unexplained. Thus, to unravel their molecular underpinnings, we sought to investigate interactions amongst GRM3, SLC1A1, SLC1A2, SLC1A3, SLC1A4 gene polymorphisms with drug response in south Indian schizophrenia patients. We genotyped 48 SNPs from these genes in 423 schizophrenia patients stratified into low and high severity of illness groups. The SNPs and haplotypic combinations of associated SNPs were examined for their association with antipsychotic response. Multifactor-dimensionality-reduction was further used to explore gene-gene interaction among these SNPs and 53 SNPs from previously studied genes (BDNF, RGS4, SLC6A3, PI4KA, and PIP4K2A). Single SNP and haplotype analyses revealed no significant association with drug response irrespective of severity of illness. Gene-gene interaction analyses yielded promising leads, including an observed synergistic effect between PI4KA_rs165854 and GRM3_rs1468412 polymorphisms and incomplete antipsychotic response in schizophrenia patients with low severity of illness (OR = 12.4; 95%CI = 3.69-41.69). Further, this interaction was also observed in atypical monotherapy (n = 355) and risperidone (n = 260) treatment subgroups (OR = 11.21; 95%CI = 3.30-38.12 and OR = 13.5; 95%CI = 3.03-121.61 respectively). PI4KA is known to be involved in the biosynthesis of phosphatidylinositol-4, 5-bisphosphate which regulates exocytotic fusion of synaptic vesicles (glutamate, dopamine) with the plasma membrane and regulates duration of signal transduction of GPCRs. Whereas GRM3 regulates glutamate and dopamine transmission. Present findings indicate that PI4KA and GRM3 polymorphisms have potential to jointly modulate antipsychotic response. These results warrant additional replication studies to shed further light on these interactions.</AbstractText>
                <CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kaur</LastName>
                    <ForeName>Harpreet</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jajodia</LastName>
                    <ForeName>Ajay</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grover</LastName>
                    <ForeName>Sandeep</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baghel</LastName>
                    <ForeName>Ruchi</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Sanjeev</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kukreti</LastName>
                    <ForeName>Ritushree</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA>
            <NlmUniqueID>101235742</NlmUniqueID>
            <ISSNLinking>1552-4841</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015778">Minor Histocompatibility Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C102718">metabotropic glutamate receptor 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.67</RegistryNumber>
                <NameOfSubstance UI="C402182">phosphatidylinositol phosphate 4-kinase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015778" MajorTopicYN="N">Minor Histocompatibility Antigens</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antipsychotics</Keyword>
            <Keyword MajorTopicYN="N">glutamatergic pathway</Keyword>
            <Keyword MajorTopicYN="N">pharmacogenomics</Keyword>
            <Keyword MajorTopicYN="N">phosphatidylinositol signaling</Keyword>
            <Keyword MajorTopicYN="N">schizophrenia</Keyword>
            <Keyword MajorTopicYN="N">severity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25209194</ArticleId>
            <ArticleId IdType="doi">10.1002/ajmg.b.32268</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26325438</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-6536</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title>
                <ISOAbbreviation>Biol. Blood Marrow Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>268-276</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1083-8791(15)00575-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2015.08.027</ELocationID>
            <Abstract>
                <AbstractText>Allelic variants of genes implicated in drug absorption, distribution, metabolism, and excretion (ADME) determine the pharmacokinetic variability of many medications and are increasingly recognized as important factors determining the success or failure of medical treatments. Both tacrolimus and sirolimus have narrow therapeutic ranges maintained by therapeutic drug monitoring (TDM). Using an ADME panel that covers &gt;99% of the PharmaADME working group core list (188 single nucleotide polymorphism [SNP] and 12 copy number variant [CNV] assays in 36 pharmacogenetically relevant genes), we studied 177 patients who underwent allogeneic hematopoietic cell transplantation (HCT) using tacrolimus/sirolimus-based graft-versus-host disease (GVHD) prophylaxis. We tested for possible associations between ADME variants and tacrolimus/sirolimus drug levels, concentration/dose (C/D) ratio, and clinical endpoints, including acute GVHD. A total of 62 SNP and 6 CNV assays were evaluable after removing the variants, which were homozygous in (nearly) all samples. For sirolimus, rs2032582 (ABCB1) T-carriers versus non-T-carriers were associated with higher blood levels (P = .01), with similar results for C/D ratio. Generalized estimating equation analysis supported these findings. For tacrolimus, rs776746 CYP3A5*3/*3 and CYP3A5*3/*1 were associated with higher blood levels than CYP3A5*1/*1 (P = .002). By multivariable analysis, rs776746 CYP3A5*3/*3 and CYP3A5*3/*1 were independently associated with decreased acute GVHD compared with CYP3A5*1/*1, after adjustment for conditioning, donor type, race/ethnicity, and age. We demonstrated association of specific ADME genetic polymorphisms with blood levels of tacrolimus/sirolimus, and incidence of acute GVHD after HCT, in spite of TDM and dose adjustment. A larger ongoing study will determine whether these associations have clinical utility beyond TDM. </AbstractText>
                <CopyrightInformation>Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khaled</LastName>
                    <ForeName>Samer K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Gehr Family Center for Leukemia Research of the Hematologic Malignancies and Stem Cell Transplantation Institute of the City of Hope, Duarte, CA. Electronic address: samerkm@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Joycelynne M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herzog</LastName>
                    <ForeName>Josef</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Cancer Genetics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stiller</LastName>
                    <ForeName>Tracey</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsai</LastName>
                    <ForeName>Ni-Chun</ForeName>
                    <Initials>NC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Senitzer</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Histocompatibility (HLA Laboratory), City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Xueli</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomas</LastName>
                    <ForeName>Sandra H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shayani</LastName>
                    <ForeName>Sepideh</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weitzel</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Cancer Genetics, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forman</LastName>
                    <ForeName>Stephen J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>Ryotaro</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA033572</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA33572</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biol Blood Marrow Transplant</MedlineTA>
            <NlmUniqueID>9600628</NlmUniqueID>
            <ISSNLinking>1083-8791</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>W36ZG6FT64</RegistryNumber>
                <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Ther. 2000;22 Suppl B:B93-100</RefSource>
                <PMID Version="1">10823377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2014 Aug 21;124(8):1372-7</RefSource>
                <PMID Version="1">24982504</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2001;40(4):283-95</RefSource>
                <PMID Version="1">11368293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2001 Jun;34(6):865-72</RefSource>
                <PMID Version="1">11451170</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2001 Dec 27;72(12):1924-9</RefSource>
                <PMID Version="1">11773890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94</RefSource>
                <PMID Version="1">12406645</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2002 Dec 15;74(11):1486-9</RefSource>
                <PMID Version="1">12490779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Blood Marrow Transplant. 2004 May;10(5):328-36</RefSource>
                <PMID Version="1">15111932</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2004 Jun;4(6):914-9</RefSource>
                <PMID Version="1">15147425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 1974 Oct;18(4):295-304</RefSource>
                <PMID Version="1">4153799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 1989;42(1):135-56</RefSource>
                <PMID Version="1">2657807</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biometrics. 1991 Sep;47(3):825-39</RefSource>
                <PMID Version="1">1742441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Biochem Biophys. 1992 May 1;294(2):454-60</RefSource>
                <PMID Version="1">1373595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone Marrow Transplant. 1998 Aug;22(3):217-25</RefSource>
                <PMID Version="1">9720734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 1998 Oct 27;66(8):1113-5</RefSource>
                <PMID Version="1">9808502</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Springer Semin Immunopathol. 2004 Nov;26(1-2):71-94</RefSource>
                <PMID Version="1">15549304</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2005 Mar;5(3):595-603</RefSource>
                <PMID Version="1">15707415</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Hematol. 2006 Jan;43(1):3-10</RefSource>
                <PMID Version="1">16412784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2006 Jul;80(1):51-60</RefSource>
                <PMID Version="1">16815317</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 2006 Oct;112(1):184-98</RefSource>
                <PMID Version="1">16759707</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Transplant. 2007 May;11(3):296-300</RefSource>
                <PMID Version="1">17430486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2007 Apr 1;109(7):3108-14</RefSource>
                <PMID Version="1">17138818</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2007 Oct;17(10):873-83</RefSource>
                <PMID Version="1">17885626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35</RefSource>
                <PMID Version="1">17965516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biopharm Drug Dispos. 2008 Jan;29(1):1-5</RefSource>
                <PMID Version="1">17941052</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2008 Apr;30(2):143-50</RefSource>
                <PMID Version="1">18367973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2008 May;18(5):413-23</RefSource>
                <PMID Version="1">18408564</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2008 May;9(5):585-96</RefSource>
                <PMID Version="1">18466104</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2008 May 15;85(9):1222-9</RefSource>
                <PMID Version="1">18475175</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pharmacol. 2008 Jul;48(7):849-89</RefSource>
                <PMID Version="1">18524998</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2010 Feb 4;115(5):1098-105</RefSource>
                <PMID Version="1">19965688</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6</RefSource>
                <PMID Version="1">19786111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2010 Jun;87(6):663-7</RefSource>
                <PMID Version="1">20220747</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Leuk Res. 2012 Sep;36(9):1152-6</RefSource>
                <PMID Version="1">22677229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Haematologica. 2012 Dec;97(12):1882-9</RefSource>
                <PMID Version="1">22689677</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304</RefSource>
                <PMID Version="1">23078784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone Marrow Transplant. 2013 Feb;48(2):278-83</RefSource>
                <PMID Version="1">23000644</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2013 Oct;14(13):1565-72</RefSource>
                <PMID Version="1">24088127</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2001 Apr;27(4):383-91</RefSource>
                <PMID Version="1">11279519</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006086" MajorTopicYN="N">Graft vs Host Disease</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Drug absorption, distribution, metabolism, and excretion (ADME)</Keyword>
            <Keyword MajorTopicYN="N">Immunosuppressant</Keyword>
            <Keyword MajorTopicYN="N">Pharmacogenetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>05</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26325438</ArticleId>
            <ArticleId IdType="pii">S1083-8791(15)00575-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbmt.2015.08.027</ArticleId>
            <ArticleId IdType="pmc">PMC4716887</ArticleId>
            <ArticleId IdType="mid">NIHMS723912</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25817604</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3492</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>445</Volume>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinica chimica acta; international journal of clinical chemistry</Title>
                <ISOAbbreviation>Clin. Chim. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>79-84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cca.2015.03.021</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-8981(15)00161-8</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to evaluate the blood exposure of and clinical responses to tacrolimus based on genetic variants of CYP3A5 and ABCB1 in patients with rheumatoid arthritis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Seventy rheumatoid arthritis patients treated with oral tacrolimus once daily were enrolled. Blood concentrations of tacrolimus and its major metabolite 13-O-demethylate at 12h after dosing were determined. The relationships between the tacrolimus pharmacokinetics and efficacy, renal function, and CYP3A5 and ABCB1 genotypes were evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Dose-normalized blood concentration of tacrolimus was significantly higher in the CYP3A5*3/*3 group than in the *1 allele carrier group. A lower metabolic ratio of 13-O-demethylate to tacrolimus was observed in the CYP3A5*3/*3 group. The ABCB1 3435TT group had higher dose-normalized blood concentrations of tacrolimus and 13-O-demethylate. The blood tacrolimus concentration was inversely correlated with the estimated glomerular filtration rate (eGFR). ABCB1 C3435T but not CYP3A5 genotype had decreased eGFR. Patients lacking the CYP3A5*3 allele had a higher incidence of tacrolimus withdrawal.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CYP3A5*3 increased the blood exposure of tacrolimus through its metabolic reduction. ABCB1 C3435T led to a higher blood exposure of tacrolimus and its major metabolite. The ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affected renal function in rheumatoid arthritis patients.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Naito</LastName>
                    <ForeName>Takafumi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. Electronic address: naitou@hama-med.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mino</LastName>
                    <ForeName>Yasuaki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aoki</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Department of Clinical Pharmaceutics and Pharmacy Practice, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirano</LastName>
                    <ForeName>Kumi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimoyama</LastName>
                    <ForeName>Kumiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Rheumatology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogawa</LastName>
                    <ForeName>Noriyoshi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Rheumatology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kagawa</LastName>
                    <ForeName>Yoshiyuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pharmaceutics and Pharmacy Practice, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawakami</LastName>
                    <ForeName>Junichi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Clin Chim Acta</MedlineTA>
            <NlmUniqueID>1302422</NlmUniqueID>
            <ISSNLinking>0009-8981</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C510164">CYP3A5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001711" MajorTopicYN="N">Biotransformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007677" MajorTopicYN="N">Kidney Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ABCB1</Keyword>
            <Keyword MajorTopicYN="N">CYP3A5</Keyword>
            <Keyword MajorTopicYN="N">Genetic variant</Keyword>
            <Keyword MajorTopicYN="N">Renal function</Keyword>
            <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
            <Keyword MajorTopicYN="N">Tacrolimus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25817604</ArticleId>
            <ArticleId IdType="pii">S0009-8981(15)00161-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cca.2015.03.021</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25760804</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2168-6238</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>72</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA psychiatry</Title>
                <ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>430-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2014.3053</ELocationID>
            <Abstract>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Alcohol use disorder is one of the leading causes of disability worldwide. While effective pharmacological treatments exist, they are efficacious only in certain individuals, contributing to their limited use. Secondary analysis of clinical trial data suggests that a functional polymorphism (rs1799971, Asn40Asp) of the µ-opioid receptor gene (OPRM1) is associated with the risk of relapse to heavy drinking following treatment with the opioid antagonist naltrexone.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To prospectively examine whether rs1799971 is predictive of naltrexone treatment response.</AbstractText>
                <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We conducted a 12-week, double-blind, randomized clinical trial of naltrexone vs placebo in individuals with alcohol dependence (intent-to-treat analysis). Participants were randomly assigned to study treatment based on the presence of 1 or 2 copies of the Asp40 allele compared with those homozygous for the Asn40 allele (2 × 2 cell design). Recruitment occurred between January 2009 and September 2013. All participants were seen in an outpatient clinical setting. A convenience sample of participants (n = 221) was recruited from 5 sites. All participants met DSM-IV criteria for alcohol dependence, with no concurrent psychotic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on illicit substances.</AbstractText>
                <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The study drug was naltrexone (50 mg) given once daily or corresponding placebo.</AbstractText>
                <AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary study outcome measure was relapse to heavy drinking measured using the timeline follow-back method.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no evidence of a genotype × treatment interaction on the primary outcome of heavy drinking (P = .32). In the Asn40 group, the observed effect of naltrexone was similar to that in previous trials (odds ratio, 0.69; 95% CI, 0.41-1.18; P = .17), with a very small naltrexone effect in the Asp40 group (odds ratio, 1.10; 95% CI, 0.52-2.31; P = .80), contrary to the pattern expected a priori. A significant reduction in heavy drinking occurred across all groups (P = .001). Other drinking outcomes, and all secondary outcomes, demonstrated similar time effects, with no genotype × treatment interaction.</AbstractText>
                <AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The results of this study do not support the hypothesis that the Asp40 allele moderates the response to naltrexone treatment. It is premature to use the Asn40Asp polymorphism as a biomarker to predict the response to naltrexone treatment of alcohol dependence.</AbstractText>
                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00831272.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oslin</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia2Mental Illness Research, Education, and Clinical Center, Center of Excellence for Substance Abuse Treatment and Evaluation, Philadelphia Veterans Affairs.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leong</LastName>
                    <ForeName>Shirley H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mental Illness Research, Education, and Clinical Center, Center of Excellence for Substance Abuse Treatment and Evaluation, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lynch</LastName>
                    <ForeName>Kevin G</ForeName>
                    <Initials>KG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berrettini</LastName>
                    <ForeName>Wade</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Brien</LastName>
                    <ForeName>Charles P</ForeName>
                    <Initials>CP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Adam J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania4Mental Illness Research, Education, and Clinical Center, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania5Center for Health Equity Researc.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rukstalis</LastName>
                    <ForeName>Margaret</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Wake Forest University, Winston-Salem, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00831272</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AA017164</GrantID>
                    <Acronym>AA</Acronym>
                    <Agency>NIAAA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Psychiatry</MedlineTA>
            <NlmUniqueID>101589550</NlmUniqueID>
            <ISSNLinking>2168-622X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>30KYC7MIAI</RegistryNumber>
                <NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5S6W795CQM</RegistryNumber>
                <NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7006-34-0</RegistryNumber>
                <NameOfSubstance UI="D001216">Asparagine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001216" MajorTopicYN="N">Asparagine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009292" MajorTopicYN="N">Narcotic Antagonists</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25760804</ArticleId>
            <ArticleId IdType="pii">2174542</ArticleId>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2014.3053</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23588952</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>10</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>139</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>135-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-013-2516-z</ELocationID>
            <Abstract>
                <AbstractText>The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer. However, toxicity and large interpatient pharmacokinetic variability occur despite body surface area (BSA)-dosing. We hypothesized that a fixed-dose schedule would simplify dosing and provide an effective and safe alternative to BSA-based dosing. We conducted an open label, single-arm, two-stage study of oral capecitabine with fixed starting dose (3,000 mg total daily dose in two divided doses × 14 days q21 days) in patients with metastatic breast cancer. We correlated pharmacodynamic endpoints [e.g., efficacy (response) per RECIST and toxicity], adherence and pharmacokinetics/pharmacogenetics. Sample size of 45 patients was required to detect a 25 % response rate from null response rate of 10 % using a Simon two-stage design. Twenty-six patients were enrolled in the first-stage and 21 were evaluable after a median of four cycles of capecitabine. Two thirds of patients received either the same dose or a dose 500 mg lower than what would have been administered with a commonly used 2,000 mg/m(2) BSA-dosing schedule. Eight patients had stable disease but progressed after a median of seven cycles. Despite a clinical benefit rate of 19 %, no RECIST responses were observed following the first stage and the study was closed. Dose-reductions were required for grade 2 hand-foot syndrome (28 %) and vomiting (5 %). Adherence was similar when using both patient-reported and Medication Event Monitoring System methods. High interpatient variability was observed for capecitabine and metabolite pharmacokinetics, but was not attributed to observed pharmacogenetic or BSA differences. Single agent activity of capecitabine was modest in our patients with estrogen receptor-positive or -negative metastatic breast cancer and comparable to recent studies. BSA was not the main source of pharmacokinetic variability. Fixed-dose capecitabine is feasible, and simplifies dosing.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rudek</LastName>
                    <ForeName>Michelle A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1-1M52, Baltimore, MD 21231, USA. mrudek2@jhmi.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Connolly</LastName>
                    <ForeName>Roisin M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoskins</LastName>
                    <ForeName>Janelle M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garrett-Mayer</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeter</LastName>
                    <ForeName>Stacie C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Armstrong</LastName>
                    <ForeName>Deborah K</ForeName>
                    <Initials>DK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fetting</LastName>
                    <ForeName>John H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stearns</LastName>
                    <ForeName>Vered</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wright</LastName>
                    <ForeName>Laurie A</ForeName>
                    <Initials>LA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watkins</LastName>
                    <ForeName>Stanley P</ForeName>
                    <Initials>SP</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLeod</LastName>
                    <ForeName>Howard L</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidson</LastName>
                    <ForeName>Nancy E</ForeName>
                    <Initials>NE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolff</LastName>
                    <ForeName>Antonio C</ForeName>
                    <Initials>AC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA006973</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 RR025005</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>3P40 CA006973-41S</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 RR 025005</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>04</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6804DJ8Z9U</RegistryNumber>
                <NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Chemother Pharmacol. 2000;45(4):291-7</RefSource>
                <PMID Version="1">10755317</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2004;4(5):307-14</RefSource>
                <PMID Version="1">15224082</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2001 Jun;59(6):1542-8</RefSource>
                <PMID Version="1">11353816</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest New Drugs. 2001 May;19(2):171-7</RefSource>
                <PMID Version="1">11392451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2002 Jun 15;20(12):2812-23</RefSource>
                <PMID Version="1">12065558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Cancer. 2002 Oct;38(15):2020-4</RefSource>
                <PMID Version="1">12376207</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):273-85</RefSource>
                <PMID Version="1">12450548</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2002 Dec 18;94(24):1822-3</RefSource>
                <PMID Version="1">12488468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8</RefSource>
                <PMID Version="1">12488482</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem. 2003 Oct;49(10):1661-4</RefSource>
                <PMID Version="1">14500593</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2004 Oct;84(4):661-8</RefSource>
                <PMID Version="1">15475243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1990 Jan 1;50(1):197-201</RefSource>
                <PMID Version="1">2293556</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 1998 Jul;16(7):2297-8</RefSource>
                <PMID Version="1">9667242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 1999 Feb;17(2):485-93</RefSource>
                <PMID Version="1">10080589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2005 Feb 1;23(4):889-98</RefSource>
                <PMID Version="1">15681535</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2005 Apr 1;23(10):2155-61</RefSource>
                <PMID Version="1">15710946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2005 Jun 10;23(17):3906-11</RefSource>
                <PMID Version="1">15851763</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Breast. 2005 Oct;14(5):368-74</RefSource>
                <PMID Version="1">16216738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Breast Cancer. 2007 Dec;7(11):857-60</RefSource>
                <PMID Version="1">18269775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2008 Apr 10;26(11):1797-802</RefSource>
                <PMID Version="1">18398145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):117-20</RefSource>
                <PMID Version="1">18562256</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2008 Sep 1;14(17):5602-9</RefSource>
                <PMID Version="1">18765554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>
                <PMID Version="1">19097774</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2009 May 14;360(20):2055-65</RefSource>
                <PMID Version="1">19439741</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2009 Dec;10(12):1145-51</RefSource>
                <PMID Version="1">19906561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2011 Sep 15;117(18):4125-31</RefSource>
                <PMID Version="1">21387266</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Breast Cancer. 2011 Dec;11(6):349-56</RefSource>
                <PMID Version="1">21856245</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Dec 1;29(34):4498-504</RefSource>
                <PMID Version="1">22025143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2012 Feb;13(2):135-44</RefSource>
                <PMID Version="1">22257523</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2001;40(2):85-104</RefSource>
                <PMID Version="1">11286326</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>02</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>04</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23588952</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-013-2516-z</ArticleId>
            <ArticleId IdType="pmc">PMC3673300</ArticleId>
            <ArticleId IdType="mid">NIHMS468395</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22882994</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1463-1326</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetes, obesity &amp; metabolism</Title>
                <ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>189-91</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1463-1326.2012.01691.x</ELocationID>
            <Abstract>
                <AbstractText>Pharmacogenetic studies revealed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporters-solute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes. One hundred forty-eight drug-naive patients with type 2 diabetes were included in the study. Genotyping for SLC22A1 rs622342, SLC22A2 rs316019 and SLC47A1 rs2289669 variants was performed using real-time PCR with subsequent melting-curve analysis. SLC47A1 rs2289669 genotype was significantly associated with the reduction in haemoglobin A1c (HbA1c) after 6 months. Twenty percentage of patients with diabetes that are homozygous for A-allele of SLC47A1 had twofold reduction in HbA1c in comparison with the patients carrying G-allele (GG + GA: 0.55 ± 0.09% vs. AA: 1.10 ± 0.18%, p = 0.018). In conclusion, the results of this study might have in future practical implication in personalised treatment of patients with type 2 diabetes.</AbstractText>
                <CopyrightInformation>© 2012 Blackwell Publishing Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tkáč</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia. Ivan.Tkac@upjs.sk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klimčáková</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Javorský</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabianová</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schroner</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hermanová</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Babjaková</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tkáčová</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>09</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Diabetes Obes Metab</MedlineTA>
            <NlmUniqueID>100883645</NlmUniqueID>
            <ISSNLinking>1462-8902</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C521869">MATE1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027701">Organic Cation Transport Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9100L32L2N</RegistryNumber>
                <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027701" MajorTopicYN="N">Organic Cation Transport Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22882994</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2012.01691.x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26856709</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1366-5804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2016</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals</Title>
                <ISOAbbreviation>Biomarkers</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience.</ArticleTitle>
            <Pagination>
                <MedlinePgn>335-41</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3109/1354750X.2016.1139002</ELocationID>
            <Abstract>
                <AbstractText Label="AIM OF WORK" NlmCategory="OBJECTIVE">To assess the impact of Cytochrome P450 3A5 (CYP3A5) and multidrug resistance-1 gene (MDR-1) single nucleotide polymorphisms on the dose and blood level of tacrolimus among liver transplanted patients.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We enrolled a prospective study of 41 liver transplanted patients. Dose-adjusted trough blood concentration (C/D ratio) was calculated. Polymerase chain reaction-restriction fragment length polymorphism followed by sequencing was done for genotyping of CYP3A5*3 (6986A &gt; G).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">At 1 week, 1 and 3 months C/D ratio were significantly lower in CYP3A5 expressers *1/*1 patients compared to non-expressers *3/*3.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CYP3A5 (6986A &gt; G) genotype, rather than MDR-1 (2677G &gt; A/T) variant, has an impact on tacrolimus pharmacokinetics.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fathy</LastName>
                    <ForeName>Mona</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Clinical and Chemical Pathology Department, Cairo University , Cairo , Egypt and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamal</LastName>
                    <ForeName>Manal</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Clinical and Chemical Pathology Department, Cairo University , Cairo , Egypt and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohy</LastName>
                    <ForeName>Abeer</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Clinical and Chemical Pathology Department, Cairo University , Cairo , Egypt and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nabil</LastName>
                    <ForeName>Ahmad</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Tropical Medicine Department, Faculty of Medicine, Cairo University , Cairo , Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Biomarkers</MedlineTA>
            <NlmUniqueID>9606000</NlmUniqueID>
            <ISSNLinking>1354-750X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004587" MajorTopicYN="N">Electrophoresis, Agar Gel</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019520" MajorTopicYN="Y">Living Donors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytochrome P450</Keyword>
            <Keyword MajorTopicYN="N">liver transplantation</Keyword>
            <Keyword MajorTopicYN="N">multidrug resistance-1</Keyword>
            <Keyword MajorTopicYN="N">tacrolimus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26856709</ArticleId>
            <ArticleId IdType="doi">10.3109/1354750X.2016.1139002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28084894</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8042</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenomics</Title>
                <ISOAbbreviation>Pharmacogenomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>265-275</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs-2016-0098</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Flavin-containing monooxygenase (FMO) variants were potentially involved in tacrolimus metabolism in kidney transplantion. The influences of FMO3 genotypes on tacrolimus elimination in Chinese liver transplant patients remained unclear.</AbstractText>
                <AbstractText Label="PATIENTS &amp; METHODS" NlmCategory="METHODS">FMO3 SNPs and CYP3A5 rs776746 were analyzed in 110 Chinese patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Donor FMO3 rs1800822 allele T and rs909530 allele T were associated with fast tacrolimus elimination. Combination of polymorphisms of donor FMO3 rs1800822 and rs909530 genotype impacted on tacrolimus elimination (p = 0.0221). The number of donor rs1800822 allele T and rs909530 allele T was confirmed to be an independent predictor of the tacrolimus concentration-to-dose ratios for weeks 2, 3 and 4 in the multivariate analysis.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Donor's FMO3 polymorphisms might affect tacrolimus elimination.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shandong Qianfoshan Hospital, Shandong University, Jinan 250014, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teng</LastName>
                    <ForeName>Mujian</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shandong Qianfoshan Hospital, Shandong University, Jinan 250014, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoqing</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qin</LastName>
                    <ForeName>Shengying</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bio-X Institutes, Key Laboratory for the Genetics of Developmental &amp; Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhong</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Zhihai</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Junwei</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary Pancreatic Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharmacogenomics</MedlineTA>
            <NlmUniqueID>100897350</NlmUniqueID>
            <ISSNLinking>1462-2416</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.-</RegistryNumber>
                <NameOfSubstance UI="D010105">Oxygenases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.8</RegistryNumber>
                <NameOfSubstance UI="C020066">dimethylaniline monooxygenase (N-oxide forming)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010105" MajorTopicYN="N">Oxygenases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014019" MajorTopicYN="Y">Tissue Donors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CYP-450 3A5</Keyword>
            <Keyword MajorTopicYN="N">FMO3</Keyword>
            <Keyword MajorTopicYN="N">pharmacogenomics</Keyword>
            <Keyword MajorTopicYN="N">tacrolimus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28084894</ArticleId>
            <ArticleId IdType="doi">10.2217/pgs-2016-0098</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21280081</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1531-8249</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>69</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of neurology</Title>
                <ISOAbbreviation>Ann. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>111-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.22155</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of this study was to determine the response to entacapone in COMT(HH) and COMT(LL) PD patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-three PD patients, homozygous for the COMT alleles COMT(HH) (n = 17) and COMT(LL) (n = 16), were randomized in a double-blind crossover trial consisting of 2 successive acute levodopa challenges associated with 200mg entacapone or placebo. The primary endpoint was the gain in the best ON time. Secondary endpoints were levodopa pharmacokinetics and COMT activity in red blood cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The gain in the best ON time was higher in COMT(HH) than in COMT(LL) patients (39 ± 10 vs 9 ± 9 minutes, p = 0.04, interaction between treatment and genotype). Area under the concentration over time curve of levodopa increased more after entacapone in COMT(HH) than in COMT(LL) patients (+62 ± 6% vs +34 ± 8%, p = 0.01). COMT inhibition by entacapone was higher in COMT(HH) than in COMT(LL) patients (-0.54 ± 0.07 vs -0.31 ± 0.06 pmol/min/mg protein, p = 0.02).</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The COMT(HH) genotype in PD patients enhances the effect of entacapone on the pharmacodynamics and pharmacokinetics of levodopa. The response to entacapone after repeated administrations and in heterozygous patients remains to be determined.</AbstractText>
                <CopyrightInformation>Copyright © 2010 American Neurological Association.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Corvol</LastName>
                    <ForeName>Jean-Christophe</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM (French National Institute of Medical Research and Health), Clinical Investigation Center (CIC-9503), Pitié-Salpêtrière Hospital, Paris, France. jean-christophe.corvol@psl.aphp.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonnet</LastName>
                    <ForeName>Cécilia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Charbonnier-Beaupel</LastName>
                    <ForeName>Fanny</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonnet</LastName>
                    <ForeName>Anne-Marie</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fiévet</LastName>
                    <ForeName>Marie-Hélène</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bellanger</LastName>
                    <ForeName>Agnès</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roze</LastName>
                    <ForeName>Emmanuel</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meliksetyan</LastName>
                    <ForeName>Gayané</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ben Djebara</LastName>
                    <ForeName>Mouna</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartmann</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lacomblez</LastName>
                    <ForeName>Lucette</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vrignaud</LastName>
                    <ForeName>Cédric</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zahr</LastName>
                    <ForeName>Noël</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agid</LastName>
                    <ForeName>Yves</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costentin</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hulot</LastName>
                    <ForeName>Jean-Sébastien</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidailhet</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Neurol</MedlineTA>
            <NlmUniqueID>7707449</NlmUniqueID>
            <ISSNLinking>0364-5134</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D065098">Catechol O-Methyltransferase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002396">Catechols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4975G9NM6T</RegistryNumber>
                <NameOfSubstance UI="C071192">entacapone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AE28F7PNPL</RegistryNumber>
                <NameOfSubstance UI="D008715">Methionine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.1.1.6</RegistryNumber>
                <NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>HG18B9YRS7</RegistryNumber>
                <NameOfSubstance UI="D014633">Valine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065098" MajorTopicYN="N">Catechol O-Methyltransferase Inhibitors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002396" MajorTopicYN="N">Catechols</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21280081</ArticleId>
            <ArticleId IdType="doi">10.1002/ana.22155</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">19749757</PMID>
        <DateCompleted>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>41</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1105-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.449</ELocationID>
            <Abstract>
                <AbstractText>The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients. We report a genome-wide association study (GWAS) to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population. We found two SNPs near the gene IL28B on chromosome 19 to be strongly associated with NVR (rs12980275, P = 1.93 x 10(-13), and rs8099917, 3.11 x 10(-15)). We replicated these associations in an independent cohort (combined P values, 2.84 x 10(-27) (OR = 17.7; 95% CI = 10.0-31.3) and 2.68 x 10(-32) (OR = 27.1; 95% CI = 14.6-50.3), respectively). Compared to NVR, these SNPs were also associated with SVR (rs12980275, P = 3.99 x 10(-24), and rs8099917, P = 1.11 x 10(-27)). In further fine mapping of the region, seven SNPs (rs8105790, rs11881222, rs8103142, rs28416813, rs4803219, rs8099917 and rs7248668) located in the IL28B region showed the most significant associations (P = 5.52 x 10(-28)-2.68 x 10(-32); OR = 22.3-27.1). Real-time quantitative PCR assays in peripheral blood mononuclear cells showed lower IL28B expression levels in individuals carrying the minor alleles (P = 0.015).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Yasuhito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishida</LastName>
                    <ForeName>Nao</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugiyama</LastName>
                    <ForeName>Masaya</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurosaki</LastName>
                    <ForeName>Masayuki</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuura</LastName>
                    <ForeName>Kentaro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakamoto</LastName>
                    <ForeName>Naoya</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakagawa</LastName>
                    <ForeName>Mina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korenaga</LastName>
                    <ForeName>Masaaki</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hino</LastName>
                    <ForeName>Keisuke</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hige</LastName>
                    <ForeName>Shuhei</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>Yoshito</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mita</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mochida</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murawaki</LastName>
                    <ForeName>Yoshikazu</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honda</LastName>
                    <ForeName>Masao</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakai</LastName>
                    <ForeName>Akito</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hiasa</LastName>
                    <ForeName>Yoichi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishiguchi</LastName>
                    <ForeName>Shuhei</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Asako</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakaida</LastName>
                    <ForeName>Isao</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imamura</LastName>
                    <ForeName>Masatoshi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>Kiyoaki</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yano</LastName>
                    <ForeName>Koji</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masaki</LastName>
                    <ForeName>Naohiko</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugauchi</LastName>
                    <ForeName>Fuminaka</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Izumi</LastName>
                    <ForeName>Namiki</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tokunaga</LastName>
                    <ForeName>Katsushi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizokami</LastName>
                    <ForeName>Masashi</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>09</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C471044">IL28B protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Pharmacogenomics. 2010 Feb;11(2):135-9</RefSource>
                <PMID Version="1">20136353</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Gastroenterology. 2010 Apr;138(4):1622-4</RefSource>
                <PMID Version="1">20175968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2009 Oct;41(10):1048-50</RefSource>
                <PMID Version="1">19749756</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hum Genet. 2008;53(10):886-93</RefSource>
                <PMID Version="1">18695938</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Nov;40(11):1324-8</RefSource>
                <PMID Version="1">18820697</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2003 Jan;4(1):63-8</RefSource>
                <PMID Version="1">12469119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2002 Oct;123(4):1061-9</RefSource>
                <PMID Version="1">12360468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2004 Sep;41(3):474-81</RefSource>
                <PMID Version="1">15336451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 2004 Mar 2;140(5):346-55</RefSource>
                <PMID Version="1">14996676</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2001 Sep 22;358(9286):958-65</RefSource>
                <PMID Version="1">11583749</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dig Dis Sci. 2009 Jun;54(6):1317-24</RefSource>
                <PMID Version="1">18958621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2007 Mar;46(3):403-10</RefSource>
                <PMID Version="1">17126448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2002 Nov;36(5 Suppl 1):S237-44</RefSource>
                <PMID Version="1">12407599</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2008 Dec;48(6):1753-60</RefSource>
                <PMID Version="1">18925643</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Genomics. 2008 Sep 22;9:431</RefSource>
                <PMID Version="1">18803882</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2006 Apr;55(4):529-35</RefSource>
                <PMID Version="1">16299039</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2003 Jan;4(1):69-77</RefSource>
                <PMID Version="1">12483210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2002 Oct;4(12):1219-25</RefSource>
                <PMID Version="1">12467763</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2002 Sep 26;347(13):975-82</RefSource>
                <PMID Version="1">12324553</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2009 May;136(5):1796-805.e6</RefSource>
                <PMID Version="1">19208361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2004 Apr;39(4):880-90</RefSource>
                <PMID Version="1">15057887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2004 Sep;53(9):1345-51</RefSource>
                <PMID Version="1">15306598</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 1994 Jun;19(6):1513-20</RefSource>
                <PMID Version="1">8188183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2008 Feb 15;180(4):2474-85</RefSource>
                <PMID Version="1">18250457</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2006 Dec;131(6):1887-98</RefSource>
                <PMID Version="1">17087946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatol Res. 2003 Mar;25(3):221-225</RefSource>
                <PMID Version="1">12697242</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002888" MajorTopicYN="N">Chromosomes, Human, Pair 19</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19749757</ArticleId>
            <ArticleId IdType="pii">ng.449</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.449</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">16433869</PMID>
        <DateCompleted>
            <Year>2006</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-5251</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>61</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.</ArticleTitle>
            <Pagination>
                <MedlinePgn>148-54</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To characterize the demographic and pharmacogenetic factors that influence interpatient variability in the plasma concentrations of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data from all samples analyzed for efavirenz in our TDM service in 2002 and 2003 were reviewed. Information on gender, age, body weight, height, race, hormonal contraceptive use (in a subset of patients), and time between sampling and last intake was recorded. PCR-restriction fragment length polymorphism analysis was performed to detect the cytochrome P450 2B6 (CYP2B6) C1459T variant (present in CYP2B6*6 and CYP2B6*7) which is associated with low CYP2B6 activity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 255 patients were included in this analysis. The median plasma efavirenz concentration was 2.50 (interquartile range: 1.85-3.55) mg l(-1). Eight patients (3.1%) were considered to have a subtherapeutic plasma concentration (&lt;1.0 mg l(-1)) and 48 (18.9%) a toxic efavirenz concentration (&gt;4.0 mg l(-1)). Gender, time after last intake, and race were the only factors that were significantly related to plasma efavirenz concentration in a multivariate analysis. No influence was observed for body weight, hormonal contraceptive use, and the presence of the CYP2B6 C1459T polymorphism.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Gender and race are important factors in determining interpatient variability in plasma efavirenz concentrations which were unaffected by the presence of the CYP2B6 C1459T polymorphism. Physicians should be particularly alert for signs of efavirenz-induced toxicity in females and non-Caucasian patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Burger</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radboud University Medical Center Nijmegen, the Netherlands. D.Burger@akf.umcn.nl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Heiden</LastName>
                    <ForeName>Ilse</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>la Porte</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Ende</LastName>
                    <ForeName>Marchina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Groeneveld</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richter</LastName>
                    <ForeName>Clemens</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koopmans</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kroon</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sprenger</LastName>
                    <ForeName>Herman</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindemans</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schenk</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Schaik</LastName>
                    <ForeName>Ron</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010078">Oxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C585599">CYP2B6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D065702">Cytochrome P-450 CYP2B6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.5.-</RegistryNumber>
                <NameOfSubstance UI="D010089">Oxidoreductases, N-Demethylating</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.7.49</RegistryNumber>
                <NameOfSubstance UI="D054303">HIV Reverse Transcriptase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE6H2O27P8</RegistryNumber>
                <NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):89-104</RefSource>
                <PMID Version="1">14574440</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2003 Dec;307(3):906-22</RefSource>
                <PMID Version="1">14551287</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antimicrob Agents Chemother. 2004 Mar;48(3):979-84</RefSource>
                <PMID Version="1">14982792</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2004 Apr 17;363(9417):1253-63</RefSource>
                <PMID Version="1">15094269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Apr 29;350(18):1850-61</RefSource>
                <PMID Version="1">15115831</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2004 Jun;26(3):267-70</RefSource>
                <PMID Version="1">15167626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6</RefSource>
                <PMID Version="1">15194512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS Care. 2004 Jul;16(5):558-64</RefSource>
                <PMID Version="1">15223524</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2004 Dec 3;18(18):2391-400</RefSource>
                <PMID Version="1">15622315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2002 Jan;71(1):57-67</RefSource>
                <PMID Version="1">11823758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1999 Dec 16;341(25):1865-73</RefSource>
                <PMID Version="1">10601505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2001 Jan 5;15(1):71-5</RefSource>
                <PMID Version="1">11192870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antimicrob Agents Chemother. 2003 Jan;47(1):130-7</RefSource>
                <PMID Version="1">12499180</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2003 Jan;73(1):20-30</RefSource>
                <PMID Version="1">12545140</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2001 Jul;11(5):399-415</RefSource>
                <PMID Version="1">11470993</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):399-400</RefSource>
                <PMID Version="1">11707679</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2001;40(12):893-905</RefSource>
                <PMID Version="1">11735608</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2003 Jul;306(1):287-300</RefSource>
                <PMID Version="1">12676886</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2003 Oct;13(10):619-26</RefSource>
                <PMID Version="1">14515060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2003 Oct;74(4):326-33</RefSource>
                <PMID Version="1">14534519</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 2004;44:499-523</RefSource>
                <PMID Version="1">14744256</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000886" MajorTopicYN="N">Anthropometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044469" MajorTopicYN="N">Continental Population Groups</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065702" MajorTopicYN="N">Cytochrome P-450 CYP2B6</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054303" MajorTopicYN="N">HIV Reverse Transcriptase</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010078" MajorTopicYN="N">Oxazines</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010089" MajorTopicYN="N">Oxidoreductases, N-Demethylating</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16433869</ArticleId>
            <ArticleId IdType="pii">BCP2536</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2005.02536.x</ArticleId>
            <ArticleId IdType="pmc">PMC1885008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26757307</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1537-162X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <MedlineDate>2016 Jan-Feb</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical neuropharmacology</Title>
                <ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>18-23</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0000000000000119</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Narcolepsy type 1 (NT1) is a chronic hypersomnia clinically characterized by daytime sleepiness and cataplexy. Narcolepsy type 1 treatments target individual symptoms: wake-promoting agents (eg, modafinil) are effective for sleepiness, antidepressants (eg, venlafaxine) on cataplexy, whereas sodium oxybate on both. Narcolepsy type 1 patients variably respond to modafinil and venlafaxine independently of individual clinical features.Given the potential influence of drug transmembrane transport (glycoprotein-P) on drug response, we explored the relation between genetic polymorphisms in the ABCB1 gene and clinical response to modafinil/venlafaxine in NT1.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Individual drug response and genotypes were assessed in 107 NT1 patients (males/females, 64/43; mean age, 38 ± 21 years) treated with modafinil and/or venlafaxine at stable doses for at least 3 months. Minisequencing was performed to detect single-nucleotide polymorphisms in ABCB1. Patients with different responses to treatment were contrasted by Fisher exact test and multivariate analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The ABCB1 diplotype was significantly associated with clinical response to modafinil, with the CGC-TTT (1236/2677/3435) being more frequent in the modafinil responder versus nonresponder group (P = 0.013). Conversely, no significant associations with clinical response to venlafaxine were found.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ABCB1 variants modulate therapeutic response to modafinil and may partly explain pharmacoresistance in NT1 patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moresco</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Departments of Biomedical and Neuromotor Sciences (DIBINEM) and †Medical and Surgical Sciences (DIMES), University of Bologna; and ‡IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riccardi</LastName>
                    <ForeName>Laura Natalia</ForeName>
                    <Initials>LN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pizza</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zenesini</LastName>
                    <ForeName>Corrado</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caporali</LastName>
                    <ForeName>Leonardo</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plazzi</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pelotti</LastName>
                    <ForeName>Susi</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Neuropharmacol</MedlineTA>
            <NlmUniqueID>7607910</NlmUniqueID>
            <ISSNLinking>0362-5664</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D065701">Cytochrome P-450 CYP3A Inducers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7D7RX5A8MO</RegistryNumber>
                <NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R3UK8X3U3D</RegistryNumber>
                <NameOfSubstance UI="C048833">modafinil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Disease" UI="C563534">Narcolepsy 1</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065701" MajorTopicYN="N">Cytochrome P-450 CYP3A Inducers</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009290" MajorTopicYN="N">Narcolepsy</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26757307</ArticleId>
            <ArticleId IdType="doi">10.1097/WNF.0000000000000119</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">18347181</PMID>
        <DateCompleted>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>14</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Mar</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Irinotecan pharmacogenetics: influence of pharmacodynamic genes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1788-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-07-1472</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Irinotecan is an important drug for the treatment of solid tumors. Although genes involved in irinotecan pharmacokinetics have been shown to influence toxicity, there are no data on pharmacodynamic genes. CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan. Polymorphisms in the drug target of camptothecins, topoisomerase I (TOP1), and downstream effectors may influence patient outcomes to irinotecan therapy. We undertook a retrospective candidate gene haplotype association study to investigate this hypothesis.</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Haplotype compositions of six candidate genes were constructed in European (n = 93), East Asian (n = 94), and West African (n = 95) populations. Haplotype-tagging single nucleotide polymorphisms (htSNP) were selected based on genealogic relationships between haplotypes. DNA samples from 107 European, advanced colorectal cancer patients treated with irinotecan-based regimens were genotyped for htSNPs as well as three coding region SNPs. Associations between genetic variants and toxicity (grade 3/4 diarrhea and neutropenia) or efficacy (objective response) were assessed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">TOP1 and TDP1 htSNPs were related to grade 3/4 neutropenia (P = 0.04) and response (P = 0.04), respectively. Patients homozygous for an XRCC1 haplotype (GGCC-G) were more likely to show an objective response to therapy than other patients (83% versus 30%; P = 0.02). This effect was also seen in a multivariate analysis (odds ratio, 11.9; P = 0.04). No genetic variants were associated with diarrhea.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first comprehensive pharmacogenetic investigation of irinotecan pharmacodynamic factors, and our findings suggest that genetic variation in the pharmacodynamic genes may influence the efficacy of irinotecan-containing therapies in advanced colorectal cancer patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hoskins</LastName>
                    <ForeName>Janelle M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marcuello</LastName>
                    <ForeName>Eugenio</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altes</LastName>
                    <ForeName>Albert</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marsh</LastName>
                    <ForeName>Sharon</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maxwell</LastName>
                    <ForeName>Taylor</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Booven</LastName>
                    <ForeName>Derek J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paré</LastName>
                    <ForeName>Laia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Culverhouse</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLeod</LastName>
                    <ForeName>Howard L</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baiget</LastName>
                    <ForeName>Montserrat</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>U01 GM63340</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7673326042</RegistryNumber>
                <NameOfSubstance UI="C051890">irinotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.-</RegistryNumber>
                <NameOfSubstance UI="C418331">UGT1A1 enzyme</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.17</RegistryNumber>
                <NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XT3Z54Z28A</RegistryNumber>
                <NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18347181</ArticleId>
            <ArticleId IdType="pii">14/6/1788</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-1472</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23107770</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0038</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>512</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jan</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Gene</Title>
                <ISOAbbreviation>Gene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>226-31</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2012.10.048</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(12)01326-1</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Tacrolimus is a widely used immunosuppressive drug in organ transplantation. The oral bioavailability of tacrolimus varies greatly between individuals and depends largely on the activity of both the cytochrome P450 3A (CYP3A) subfamily and P-glycoprotein (P-gp). The possible influence of single nucleotide polymorphisms (SNPs) of CYP3A subfamily and P-gp (MDR-1) in liver transplant recipients has recently been indicated as one of the most important variables affecting the pharmacokinetics of tacrolimus and the renal injury induced by tacrolimus.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 216 liver transplant recipients were enrolled in this study. The recipients' mean follow-up time was 52 mo (range from 16 to 96 mo). All liver transplant recipients were all in a stable stage with normal serum creatinine (SCr). All liver transplant recipients treated with tacrolimus were genotyped for CYP3A5 (6986A&gt;G), CYP3A4 intron 6 (CYP3A4*22), MDR-1 exon 26 (3435C&gt;T) and exon 12 (1236 C&gt;T) SNPs by HRM analysis (high-resolution melting curve analysis). Recipients were defined as the early renal injury by the elevation of different microproteins in the urine including microalbumin (MA), urine immunoglobulin G (IGU), urine transferrin (TRU) and α1-microglobulin (A1M).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The daily dose of tacrolimus was higher for recipients with CYP3A5 1/1 (AA) genotype than those with CYP3A5 3/ 3 (GG) genotype [3.0 (2.0-4.0) versus 2.0 (1.5-2.5) mg/d, P&lt;0.05]. The concentration/dose ratio of recipients with CYP3A5 1 homozygotes was lowest compared to recipients with CYP3A5 3/ 3 and CYP3A5 1/ 3 genotypes. Furthermore, the recipients carrying CYP3A5 3 allele were associated with increased risk of early renal glomerular injury compared to the recipients carrying CYP3A5 1 allele (P=0.01). MDR-1 polymorphisms were not related with tacrolimus pharmacokinetics and early renal injury.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CYP3A5 6986A&gt;G genetic polymorphism affected daily dose requirements, concentration and nephrotoxicity of tacrolimus. Screening for this single nucleotide polymorphism before the transplantation might be helpful for the selection of adequate initial daily dose and to achieve the desired immunosuppression outcome.</AbstractText>
                <CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Yunying</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Jiangtao</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Junlong</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zou</LastName>
                    <ForeName>Yuangao</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Bei</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lanlan</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Gene</MedlineTA>
            <NlmUniqueID>7706761</NlmUniqueID>
            <ISSNLinking>0378-1119</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020168">ATP-Binding Cassette, Sub-Family B, Member 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.67</RegistryNumber>
                <NameOfSubstance UI="C510163">CYP3A4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C510164">CYP3A5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Pharmacogenomics. 2013 May;14(7):719-21</RefSource>
                <PMID Version="1">23651019</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020168" MajorTopicYN="N">ATP-Binding Cassette, Sub-Family B, Member 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>04</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2012</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23107770</ArticleId>
            <ArticleId IdType="pii">S0378-1119(12)01326-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.gene.2012.10.048</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24433464</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1365-2125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>78</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>135-44</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.12325</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">A large interindividual variability in plasma concentrations has been reported in patients treated with donepezil, the most frequently prescribed antidementia drug. We aimed to evaluate clinical and genetic factors influencing donepezil disposition in a patient population recruited from a naturalistic setting.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A population pharmacokinetic study was performed including data from 129 older patients treated with donepezil. The patients were genotyped for common polymorphisms in the metabolic enzymes CYP2D6 and CYP3A, in the electron transferring protein POR and the nuclear factor NR1I2 involved in CYP activity and expression, and in the drug transporter ABCB1.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average donepezil clearance was 7.3 l h(-1) with a 30% interindividual variability. Gender markedly influenced donepezil clearance (P &lt; 0.01). Functional alleles of CYP2D6 were identified as unique significant genetic covariate for donepezil clearance (P &lt; 0.01), with poor metabolizers and ultrarapid metabolizers demonstrating, respectively, a 32% slower and a 67% faster donepezil elimination compared with extensive metabolizers.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The pharmacokinetic parameters of donepezil were well described by the developed population model. Functional alleles of CYP2D6 significantly contributed to the variability in donepezil disposition in the patient population and should be further investigated in the context of individual dose optimization to improve clinical outcome and tolerability of the treatment.</AbstractText>
                <CopyrightInformation>© 2014 The British Pharmacological Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Noetzli</LastName>
                    <ForeName>Muriel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Hospital of Cery, Lausanne University Hospital, Prilly, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guidi</LastName>
                    <ForeName>Monia</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebbing</LastName>
                    <ForeName>Karsten</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eyer</LastName>
                    <ForeName>Stephan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilhelm</LastName>
                    <ForeName>Laurence</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michon</LastName>
                    <ForeName>Agnès</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomazic</LastName>
                    <ForeName>Valérie</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stancu</LastName>
                    <ForeName>Ioana</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alnawaqil</LastName>
                    <ForeName>Abdel-Messieh</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bula</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zumbach</LastName>
                    <ForeName>Serge</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaillard</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giannakopoulos</LastName>
                    <ForeName>Panteleimon</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>von Gunten</LastName>
                    <ForeName>Armin</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Csajka</LastName>
                    <ForeName>Chantal</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eap</LastName>
                    <ForeName>Chin B</ForeName>
                    <Initials>CB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007189">Indans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C110809">pregnane X receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8SSC91326P</RegistryNumber>
                <NameOfSubstance UI="C076946">donepezil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019389">Cytochrome P-450 CYP2D6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.6.2.4</RegistryNumber>
                <NameOfSubstance UI="D009251">NADPH-Ferrihemoprotein Reductase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2009;48(12):761-804</RefSource>
                <PMID Version="1">19902987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Health Syst Pharm. 1997 Dec 15;54(24):2805-10</RefSource>
                <PMID Version="1">9428950</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:7-12</RefSource>
                <PMID Version="1">9839759</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nucl Med. 2007 Jan;48(1):81-7</RefSource>
                <PMID Version="1">17204702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2008 Aug;30(4):474-82</RefSource>
                <PMID Version="1">18641553</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2006 Sep;62(9):721-6</RefSource>
                <PMID Version="1">16845507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Comput Methods Programs Biomed. 2005 Sep;79(3):241-57</RefSource>
                <PMID Version="1">16023764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:30-4</RefSource>
                <PMID Version="1">9839763</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2011 Apr;33(2):227-38</RefSource>
                <PMID Version="1">21383648</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CMAJ. 2003 Sep 16;169(6):557-64</RefSource>
                <PMID Version="1">12975222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2011 Mar;21(3):152-61</RefSource>
                <PMID Version="1">20216335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2011 Apr;21(4):225-30</RefSource>
                <PMID Version="1">20859244</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1997 Feb;60(2):284-95</RefSource>
                <PMID Version="1">9012401</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2009 Nov;19(11):877-83</RefSource>
                <PMID Version="1">19801957</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dementia. 1996 Nov-Dec;7(6):293-303</RefSource>
                <PMID Version="1">8915035</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2011 Jan;67(1):47-54</RefSource>
                <PMID Version="1">20931330</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2006 Dec;80(6):668-81</RefSource>
                <PMID Version="1">17178267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:13-8</RefSource>
                <PMID Version="1">9839760</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacopsychiatry. 2011 Sep;44(6):195-235</RefSource>
                <PMID Version="1">21969060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2008 Nov;9(11):1695-709</RefSource>
                <PMID Version="1">19018724</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Neuropharmacol. 2010 Mar-Apr;33(2):74-8</RefSource>
                <PMID Version="1">19935404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Clin Pharmacol Ther Toxicol. 1993 May;31(5):223-9</RefSource>
                <PMID Version="1">8314652</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Alzheimer Res. 2007 Sep;4(4):479-500</RefSource>
                <PMID Version="1">17908053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2009;48(11):689-723</RefSource>
                <PMID Version="1">19817501</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2011 Nov;67(11):1147-57</RefSource>
                <PMID Version="1">21630031</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Geriatr Psychiatry. 2004 Jul;19(7):624-33</RefSource>
                <PMID Version="1">15254918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS Lett. 1996 Aug 19;392(1):30-4</RefSource>
                <PMID Version="1">8769309</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 2007 Jul;50(1):21-35</RefSource>
                <PMID Version="1">17591522</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurology. 2009 Sep 8;73(10):761-7</RefSource>
                <PMID Version="1">19738170</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2005 Jul;61(5-6):361-8</RefSource>
                <PMID Version="1">15912389</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Neurol. 1999 Nov;56(11):1388-93</RefSource>
                <PMID Version="1">10555660</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:25-9</RefSource>
                <PMID Version="1">9839762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pharmacol. 1993 Nov;33(11):1086-91</RefSource>
                <PMID Version="1">8300891</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2008 Dec;30(6):689-99</RefSource>
                <PMID Version="1">18978522</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2010 Mar;332(3):1088-99</RefSource>
                <PMID Version="1">19934400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2008 Jan;36(1):169-81</RefSource>
                <PMID Version="1">17925385</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019389" MajorTopicYN="N">Cytochrome P-450 CYP2D6</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009251" MajorTopicYN="N">NADPH-Ferrihemoprotein Reductase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011987" MajorTopicYN="N">Receptors, Steroid</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CYP2D6</Keyword>
            <Keyword MajorTopicYN="N">CYP3A</Keyword>
            <Keyword MajorTopicYN="N">NR1I2</Keyword>
            <Keyword MajorTopicYN="N">POR</Keyword>
            <Keyword MajorTopicYN="N">donepezil</Keyword>
            <Keyword MajorTopicYN="N">population pharmacokinetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24433464</ArticleId>
            <ArticleId IdType="doi">10.1111/bcp.12325</ArticleId>
            <ArticleId IdType="pmc">PMC4168388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">16267764</PMID>
        <DateCompleted>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0022-1899</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>192</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Dec</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1931-42</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A. Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Adult AIDS Clinical Trials Group study 384 randomized antiretroviral-naive subjects to receive efavirenz and/or nelfinavir plus 2 nucleoside analogues, with follow-up lasting up to 3 years. Population pharmacokinetics were estimated from a nonlinear mixed-effects model. Polymorphisms in CYP2B6, CYP2C19, CYP3A4, CYP3A5, and MDR1 were characterized.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 504 participants in the genetic study included 340 efavirenz recipients and 348 nelfinavir recipients (184 of the 504 participants received both efavirenz and nelfinavir). Of the participants, 49% were white, 31% were black, and 19% were Hispanic. Plasma exposure to efavirenz and nelfinavir in each population was significantly associated with the polymorphisms CYP2B6 516G--&gt;T and CYP2C19 681G--&gt;A, respectively. Among efavirenz recipients, the MDR1 position 3435 TT genotype was associated with decreased likelihood of virologic failure and decreased emergence of efavirenz-resistant virus but not with plasma efavirenz exposure. Among nelfinavir recipients, a trend toward decreased virologic failure was associated with the polymorphism CYP2C19 681G--&gt;A.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Genetic variants predict plasma exposure to efavirenz and nelfinavir, and they may predict virologic failure and/or emergence of drug-resistant virus. These associations with treatment responses must be validated in other studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Haas</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt University School of Medicine, Nashville, TN 37203, USA. david.w.haas@vanderbilt.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smeaton</LastName>
                    <ForeName>Laura M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shafer</LastName>
                    <ForeName>Robert W</ForeName>
                    <Initials>RW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robbins</LastName>
                    <ForeName>Gregory K</ForeName>
                    <Initials>GK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morse</LastName>
                    <ForeName>Gene D</ForeName>
                    <Initials>GD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Labbe</LastName>
                    <ForeName>Line</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilkinson</LastName>
                    <ForeName>Grant R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clifford</LastName>
                    <ForeName>David B</ForeName>
                    <Initials>DB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Aquila</LastName>
                    <ForeName>Richard T</ForeName>
                    <Initials>RT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Gruttola</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pollard</LastName>
                    <ForeName>Richard B</ForeName>
                    <Initials>RB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merigan</LastName>
                    <ForeName>Thomas C</ForeName>
                    <Initials>TC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirsch</LastName>
                    <ForeName>Martin S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>George</LastName>
                    <ForeName>Alfred L</ForeName>
                    <Initials>AL</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donahue</LastName>
                    <ForeName>John P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Richard B</ForeName>
                    <Initials>RB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AI25903</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI27658</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI27659</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI27666</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI29193</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI38855</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI38858</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI46339</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AI54999</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>GM31304</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL65962</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>NS32228</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RR000095</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020168">ATP-Binding Cassette, Sub-Family B, Member 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010078">Oxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9035-51-2</RegistryNumber>
                <NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>HO3OGH5D7I</RegistryNumber>
                <NameOfSubstance UI="D019888">Nelfinavir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE6H2O27P8</RegistryNumber>
                <NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D020168" MajorTopicYN="N">ATP-Binding Cassette, Sub-Family B, Member 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019380" MajorTopicYN="Y">Anti-HIV Agents</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003577" MajorTopicYN="N">Cytochrome P-450 Enzyme System</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019888" MajorTopicYN="Y">Nelfinavir</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010078" MajorTopicYN="Y">Oxazines</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018894" MajorTopicYN="Y">Reverse Transcriptase Inhibitors</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>06</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>09</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16267764</ArticleId>
            <ArticleId IdType="pii">JID34852</ArticleId>
            <ArticleId IdType="doi">10.1086/497610</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23557867</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0946-1965</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>51</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of clinical pharmacology and therapeutics</Title>
                <ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>466-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5414/CP201836</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Both cyclosporine and tacrolimus display a narrow therapeutic index as well as high interindividual pharmacokinetic variability. We approached the effect of the CYP3A4*18B and CYP3A5*3 polymorphisms and haplotypes on the whole blood cyclosporine or tacrolimus concentration in Chinese renal transplant patients during the first month after transplantation.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A total of 83 recipients receiving tacrolimus or cyclosporine was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The whole blood concentration was measured by enzyme-multiplied immunoassay technique.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both CYP3A4*18B and CYP3A5*3 polymorphisms affected the tacrolimus dose-adjusted trough concentration (C0/D). The tacrolimus C0/D was higher in carriers of haplotype GG compared with the non-carriers. The cyclosporine dose-adjusted 2-hour post-dose concentrations (C2/D), dose-adjusted C0 + C2 ((C0 + C2)/D) and C2/C0 during Days 15 - 21 displayed significant difference among the three genotypes. Statistical difference was observed between CYP3A4*1/*1 and CYP3A4*18B/*18B groups and between CYP3A4*1/*18B and CYP3A4*18B/*18B groups, but no difference was detected between CYP3A4*1/*1 and CYP3A4*1/*18B groups. No difference was found in C0/D among the three genotypes of CYP3A4*18B polymorphism, and neither CYP3A5*3 polymorphisms nor CYP3A haplotype-derived genotypes affected the cyclosporine dose-adjusted concentration.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Genetic polymorphisms of CYP3A5*3 and CYP3A4*18B may be partly responsible in large interindividual variability of cyclosporine and tacrolimus blood levels in Chinese renal transplant patients during the first month after transplantation. A patient carried combined genotype of CYP3A4*1/*1-CYP3A5* 3/*3 might require lower tacrolimus doses to achieve target concentration levels. Genotyping of CYP3A4*18B and CYP3A5*3 before transplantation is of benefit in determining a suitable initial dose for each patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Dan-ying</ForeName>
                    <Initials>DY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacy Department, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teng</LastName>
                    <ForeName>Rui-chen</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Huai-jun</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Yun</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Int J Clin Pharmacol Ther</MedlineTA>
            <NlmUniqueID>9423309</NlmUniqueID>
            <ISSNLinking>0946-1965</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>83HN0GTJ6D</RegistryNumber>
                <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-49-2</RegistryNumber>
                <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.67</RegistryNumber>
                <NameOfSubstance UI="C510163">CYP3A4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C510164">CYP3A5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012150" MajorTopicYN="Y">Polymorphism, Restriction Fragment Length</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23557867</ArticleId>
            <ArticleId IdType="pii">10556</ArticleId>
            <ArticleId IdType="doi">10.5414/CP201836</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>